About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? [email protected]

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Atacicept in Subjects With Optic Neuritis

NCT00624468·28 sites·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

EMD Serono

With

Merck KGaA, Darmstadt, Germany

Age

18–60

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

Diagnosis of unilateral symptomatic optic neuritis as first clinical manifestation within 28 days between onset of symptoms and study Day 1

You may not be if

Pre treatment with immunosuppressants and immunomodulating drugs
Relevant cardiac, hepatic and renal diseases
Clinical significant abnormalities in blood cell counts and immunoglobulin levels
Clinical significant acute or chronic infections

The record

StatusTerminated

PhasePhase 2

Taking part34

StartedJun 2008

UpdatedFeb 17, 2016

Conditions

Where28

Research Site
Birmingham, Alabama, United States
Research Site
Aurora, Colorado, United States
Research Site
Fairfield, Connecticut, United States

Clareo Health | Atacicept in Subjects With Optic Neuritis